Hepatology Highlights
Read
838
Timeswas read the article
310
Total PDF
528
Total HTML
Share statistics
array:23 [ "pii" => "S1665268119316497" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31649-7" "estado" => "S300" "fechaPublicacion" => "2010-04-01" "aid" => "71335" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2010" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2010;9:117-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 56 "formatos" => array:3 [ "EPUB" => 15 "HTML" => 18 "PDF" => 23 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119316503" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31650-3" "estado" => "S300" "fechaPublicacion" => "2010-04-01" "aid" => "71336" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "rev" "cita" => "Ann Hepatol. 2010;9:120-32" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 53 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 18 "PDF" => 27 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Prevention of hepatocellular carcinoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "120" "paginaFinal" => "132" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Michael C. Kew" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Michael C." "apellidos" => "Kew" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119316503?idApp=UINPBA00004N" "url" => "/16652681/0000000900000002/v1_201907070740/S1665268119316503/v1_201907070740/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Hepatology Highlights" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "117" "paginaFinal" => "119" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Eric M. Yoshida, Nahum Méndez-Sánchez" "autores" => array:2 [ 0 => array:4 [ "preGrado" => "MD, MHSc, FRCP(C), FACP, FACG" "nombre" => "Eric M." "apellidos" => "Yoshida" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] 1 => array:3 [ "nombre" => "Nahum" "apellidos" => "Méndez-Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff2" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Division of Gastroenterology, University of British Columbia" "etiqueta" => "*" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Liver Research Unit. Medica Sur Clinic and Foundation, Mexico City, Mexico" "etiqueta" => "**" "identificador" => "aff2" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Correspondence and reprint request:" ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?</span><p id="p0005" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Ciesek S, et al.</span></span> Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.</p><p id="p0010" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Singham, et al.</span></span> Throughout most of its history, primary biliary cirrhosis (PBC) and chronic hepatitis B (HBV), were considered the “yin and yang” of indications for liver transplantations.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Transplantation was considered virtually curative for the former disease and, until the mid-1990s, the latter was considered futile and an absolute contraindication for transplantation due to a very high incidence of graft re-infection resulting in poor outcomes.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Needless to say, much has changed since the early days of transplantation. Graft recurrence of primary biliary cirrhosis is a well-recognized phenomenon<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> that usually occurs late post-transplant and is typically mild, although graft loss can rarely occur.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> With the introduction of passive immunization with hepatitis B immune globulin (HBIG),<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> liver transplantation has become very feasible for those suffering from HBV. Initially most centers employed protocols requiring high dose intravenous HBIG,<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> however, the development of relatively effective antiviral agents has allowed for the use of combination prophylaxis protocols utilizing low dose intramuscular HBIG<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> in combination with oral antiviral agents. The low dose intramuscular HBIG protocols were an improvement in prophylaxis delivery that became more convenient, albeit sometimes painful, for patients and easier for the post-transplant clinic nursing staff. Today, liver transplant recipients undergoing transplantation for PBC and HBV enjoy excellent post-transplant outcomes.</p><p id="p0015" class="elsevierStylePara elsevierViewall">In this current issue of the Annals, two liver transplant papers appear that explore post-transplant PBC recurrence and HBIG administration post-transplant even further. Dr. Ciesek and colleagues from Hannover Germany report an interesting paper studying the possible role of anti-parietal cell autoan-tibodies (PCA) as a marker for post-transplant PBC recurrence. PCA are well-known to be present in atrophic gastritis and can also be found in PBC. Cie-sek et al reported that PCA were present in just under half of their PBC pre-transplant patients but appeared in 1007 of liver transplant recipients with PBC recurrence. Although it remains to be explained why this has occurred, especially given the post-transplant immunosuppression that liver transplant recipients require (and Cisek et al did not find any significant differences in immunosuppressive regi-mins amongst their PBC recurrence patients), this finding has not been previously reported and is both hypothesis generating and worthy of future studies. With regards to post-transplant HBIG administration, Dr. Singham and colleagues from the University of British Columbia, report on a pilot study of a subcutaneous (SC) HBIG maintenance protocol. The SC protocol achieved the HBIG maintenance titres and was very well-tolerated. In fact, all of the patients enrolled in the SC protocol preferred the study protocol compared to their previous intramuscular protocol because of less pain at the injection site. Although a SC maintenance protocol will require further clinical studies before it can be considered standard of care, it may represent an improvement on existing HBIG protocols.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Serum concentrations of substance P in cholestasis</span><p id="p0020" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Trivedi M, Bergasa NV.</span></span> Both patients suffering from cholestatic liver disease (e.g. primary biliary cirrhosis) and their hepatologists/gas-troenterologists are all too familiar with pruritis that ranges from mild to severe and debilitating. Relatively effective medications are often prescribed including rifampin<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> and, in rifampin-refrac-tory cases, naltrexone.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Although these medications often work, sometimes surprisingly so, the truth is that they are prescribed empirically and clinicians do not know the precise cause/ mediator of the pruritis of cholestasis. In this issue of the Annals, Drs. Trevedi and Bergasa, from the State University of New York and the New York Medical College respectively, report an interesting paper that studied the serum concentrations of substance P in pruritic patients with choles-tatic liver disease, non-pruritic patients with cho-lestatic liver disease and a control group that did not have liver disease at all. Serum levels of substance P were markedly elevated in the cholestatic patients with pruritis but not in the two other comparator groups. Trevedi and Bergasa then followed this clinical study with an animal model utilizing rats that had undergone bile duct liga-tion. Again, they found that the rats that underwent bile duct ligation had elevated serum substance P compared to rats that did not undergo bile duct ligation. This interesting paper may shed some light on the mechanism of cholestatic associated pruritis. From a clinical perspective, it may also suggest a relatively simple laboratory test that can distinguish pruritis of cholestastic liver disease from the common non-liver disease causes of itching (ie. dry skin etc).</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents</span><p id="p0025" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold"><span class="elsevierStyleItalic">Al Ali J, et al.</span></span> Hepatitis C (HCV) is a common infection throughout North America, Latin America and the rest of the world, a fact that is all too well known to the readers of the Annals. Many, many clinical trials of its treatment have been published as part of the drug registration process of interfe-ron-based therapy in combination with ribavirin. HCV genotype 4, however, is relatively uncommon in North America and Latin America, but is a very common, as well as serious, clinical problem in the Middle East. Despite the fact that a few clinical studies of peginteferon and ribavirin in genotype 4 adult patients have been published from Egypt10 and Saudi Arabia,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> the published outcomes of genotype 4 patients in the pediatric/adolescent population are distinctly rare. In this issue of the Annals, Dr. Al Ali and colleagues from the Kuwait University report on the outcomes of peginterferon and ri-bavirin combination therapy in a group of adolescents. Similar to the adult genotype 4 therapeutic experience,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> the outcomes in the adolescent population are also excellent with a 75% sustained virologic response and excellent patient compliance. The publication of interesting paper, aside from its contribution to the pediatric hepatology literature, also signifies the truly international nature of the Annals and that the audience of the Annals is a world-wide one that goes well beyond North America and, Latin America.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Serum concentrations of substance P in cholestasis" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents" ] 3 => array:1 [ "titulo" => "Reference" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Reference" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:11 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Selection of patients for liver transplantation in 1997 and beyond" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Yoshida E.M." 1 => "Lake J.R." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Liv Dise" "fecha" => "1997" "volumen" => "1" "paginaInicial" => "247" "paginaFinal" => "261" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Liver transplantation in European patients with the hepatitis B surface antigen" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Samuel D." 1 => "Muller R." 2 => "Alexander G." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199312163292503" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1993" "volumen" => "329" "paginaInicial" => "1842" "paginaFinal" => "1847" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8247035" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Late recurrent post-transplant primary biliary cirrhosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Yoshida E.M." 1 => "Singh R.A." 2 => "Vartanian R.K." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Can J Gastroenterology" "fecha" => "1997" "volumen" => "11" "paginaInicial" => "229" "paginaFinal" => "233" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recurrence of primary biliary cirrhosis after liver transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Neuberger J." 1 => "Portmann B." 2 => "Macdougall B.R.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM198201073060101" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1982" "volumen" => "306" "paginaInicial" => "1" "paginaFinal" => "4" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7031471" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence of disease recurrence after liver transplantation for primary biliary cirrhosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Polson R.J." 1 => "Portmann B." 2 => "Neuberger J." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "1989" "volumen" => "97" "paginaInicial" => "715" "paginaFinal" => "725" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2666253" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "McGory R.W." 1 => "Ishitani M.B." 2 => "Oliverira W.M." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Transplantation" "fecha" => "1996" "volumen" => "61" "paginaInicial" => "1358" "paginaFinal" => "1364" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8629297" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0022346815002183" "estado" => "S300" "issn" => "00223468" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Yoshida E.M." 1 => "Erb S." 2 => "Partovi N." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Liver Transpl Surg" "fecha" => "1999" "volumen" => "5" "paginaInicial" => "520" "paginaFinal" => "525" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10545541" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rifampin is safe for treatment of pruritis due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Khurana S." 1 => "Singh P." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1478-3231.2006.01326.x" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2006" "volumen" => "26" "paginaInicial" => "943" "paginaFinal" => "948" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16953834" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral naltrexone treatment for cholestatic pruritis: a double-blind placebo-controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Wolfhagen F.H." 1 => "Sternieri E." 2 => "Hop W.C." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "1997" "volumen" => "113" "paginaInicial" => "1264" "paginaFinal" => "1269" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9322521" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pegylated interferon alpha 2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Kamal S.M." 1 => "El Kamary S.S." 2 => "Shardell M.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.21917" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "1732" "paginaFinal" => "1740" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17943989" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ustained virologic response in a predominantly hepatitis C virus genotype 4 infected population" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Dahlan Y." 1 => "Ather H.M." 2 => "Al-ahmadi M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.15.4429" "Revista" => array:6 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2009" "volumen" => "15" "paginaInicial" => "4429" "paginaFinal" => "4433" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19764095" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000000900000002/v1_201907070740/S1665268119316497/v1_201907070740/en/main.assets" "Apartado" => array:4 [ "identificador" => "77938" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Hepatology highlights" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000000900000002/v1_201907070740/S1665268119316497/v1_201907070740/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119316497?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 0 | 1 |
| 2024 October | 6 | 4 | 10 |
| 2024 September | 12 | 0 | 12 |
| 2024 August | 14 | 3 | 17 |
| 2024 July | 10 | 1 | 11 |
| 2024 June | 4 | 3 | 7 |
| 2024 May | 6 | 2 | 8 |
| 2024 April | 6 | 4 | 10 |
| 2024 March | 10 | 1 | 11 |
| 2024 February | 12 | 8 | 20 |
| 2024 January | 6 | 4 | 10 |
| 2023 December | 1 | 4 | 5 |
| 2023 November | 9 | 2 | 11 |
| 2023 October | 10 | 2 | 12 |
| 2023 September | 4 | 1 | 5 |
| 2023 August | 4 | 3 | 7 |
| 2023 July | 4 | 2 | 6 |
| 2023 June | 17 | 2 | 19 |
| 2023 May | 35 | 1 | 36 |
| 2023 April | 27 | 0 | 27 |
| 2023 March | 15 | 2 | 17 |
| 2023 February | 20 | 4 | 24 |
| 2023 January | 11 | 2 | 13 |
| 2022 December | 5 | 3 | 8 |
| 2022 November | 11 | 5 | 16 |
| 2022 October | 5 | 5 | 10 |
| 2022 September | 9 | 7 | 16 |
| 2022 August | 6 | 5 | 11 |
| 2022 July | 9 | 5 | 14 |
| 2022 June | 8 | 6 | 14 |
| 2022 May | 7 | 4 | 11 |
| 2022 April | 12 | 11 | 23 |
| 2022 March | 26 | 9 | 35 |
| 2022 February | 17 | 6 | 23 |
| 2022 January | 28 | 4 | 32 |
| 2021 December | 10 | 7 | 17 |
| 2021 November | 7 | 13 | 20 |
| 2021 October | 11 | 8 | 19 |
| 2021 September | 10 | 8 | 18 |
| 2021 August | 2 | 3 | 5 |
| 2021 July | 7 | 4 | 11 |
| 2021 June | 3 | 9 | 12 |
| 2021 May | 8 | 5 | 13 |
| 2021 April | 14 | 6 | 20 |
| 2021 March | 5 | 9 | 14 |
| 2021 February | 4 | 5 | 9 |
| 2021 January | 6 | 4 | 10 |
| 2020 December | 3 | 6 | 9 |
| 2020 November | 4 | 7 | 11 |
| 2020 October | 3 | 4 | 7 |
| 2020 September | 7 | 4 | 11 |
| 2020 August | 5 | 4 | 9 |
| 2020 July | 3 | 4 | 7 |
| 2020 June | 3 | 4 | 7 |
| 2020 May | 5 | 3 | 8 |
| 2020 April | 1 | 13 | 14 |
| 2020 March | 2 | 24 | 26 |
| 2020 February | 1 | 10 | 11 |
| 2020 January | 4 | 3 | 7 |
| 2019 December | 2 | 4 | 6 |
| 2019 November | 5 | 5 | 10 |
| 2019 October | 1 | 2 | 3 |
| 2019 September | 1 | 2 | 3 |
| 2019 August | 1 | 1 | 2 |
| 2019 July | 3 | 4 | 7 |
Show all
